GlassScriptPhysician profile
Kenneth R Mirkin
NPI 1952372542
$3,973.53
in general payments reported to CMS, 2019-2025
27 companies · $18.81 in 2025
The $18.81 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $416 · 2021: $227 · 2022: $1,059 · 2023: $1,130 · 2024: $13.36 · 2025: $18.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Education: $29.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.26 |
| Education | $29.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.37 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $505.49 | 2019-2023 | Entyvio |
| Pfizer INC. | $424.62 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.82 | 2019-2023 | Xifaxan, Trulance |
| Celgene Corporation | $288.10 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $275.43 | 2019-2025 | Stelara, Remicade, Simponi |
| Ferring Pharmaceuticals INC. | $132.26 | 2019-2023 | Rebyota |
| Genzyme Corporation | $78.13 | 2022-2023 | |
| Amgen INC. | $70.21 | 2020-2023 | Amjevita, Avsola |
| Regeneron Healthcare Solutions, INC. | $65.68 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $60.29 | 2022-2023 | Ocaliva |
| Daiichi Sankyo INC. | $59.35 | 2020-2023 | Injectafer |
| Gilead Sciences, INC. | $57.60 | 2020-2023 | |
| Braintree Laboratories, INC. | $41.59 | 2022-2023 | Sutab |
| Fresenius Kabi USA, LLC | $34.86 | 2023 | Idacio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $29.87 | 2020-2022 | |
| Celltrion USA INC. | $29.15 | 2023 | Yuflyma |
| Alfasigma USA, INC. | $29.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.18 | 2022 | |
| Ucb, INC. | $16.13 | 2019 | |
| Merck Sharp & Dohme LLC | $14.63 | 2019 | |
| Capsovision, INC. | $13.36 | 2024 | Capsocam Plus |
| Endo Pharmaceuticals INC. | $12.46 | 2019 | |
| W. L. Gore & Associates, INC. | $11.83 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.10 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mirkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.